-

Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, announced the appointment of Mandar Borkar as Global Chief Financial Officer (CFO) and Ross Oehler as Global Chief Legal Officer (CLO).

“We are pleased to welcome Mandar Borkar and Ross Oehler to the management team,” said Chirag and Chintu Patel, Co-Founders of Kashiv BioSciences, “With two approved products on the market and a rapidly advancing pipeline, we are confident their expertise will play a pivotal role in advancing Kashiv to new heights.”

Mandar Borkar brings over 25 years of experience in the pharmaceutical industry managing complex financial structures, leading M&A and finance transformation, and governing global finance teams. Mr. Borkar’s career includes roles at Mahindra & Mahindra, Parke Davis, Lupin, and Watson Pharma. As CFO of Indoco Remedies, he optimized operational efficiency and positioned the company for long-term financial growth. Most recently, Mr. Borkar led Abbott’s Financial Controlling Function, ensured Financial Reporting and Compliance, and drove advancements in finance operations. He is a member of the Institute of Chartered Accountants of India and Institute of Cost and Management Accountants of India. Mr. Borkar holds a B Com from Mumbai University.

Ross Oehler brings over 30 years of biopharmaceutical experience from Sanofi-Aventis, Cephalon Inc., and Johnson Matthey, Inc., handling complex legal matters. Mr. Oehler heads the global Legal and IP groups, providing support on matters including IP, litigation, corporate governance, regulatory policy, compliance, and commercial transactions. Mr. Oehler has been involved in numerous IP and commercial disputes in the US Federal Courts, International Trade Commission, and post-grant review proceedings in US and European Patent Offices. He is a member of the Association of Corporate Counsel, Association of Corporate Patent Counsel, and served on the Board of Directors of the IP Owners Association. Mr. Oehler holds a JD from New York Law School and Bachelor’s degree in Biology from Gettysburg College.

About Kashiv:

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. Kashiv BioSciences, LLC in the United States, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.

Kashiv BioSciences, LLC


Release Versions

More News From Kashiv BioSciences, LLC

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This acquisition combines Kashiv’s extensive expertise in the development and manufacturing o...

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey. Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across mu...

Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company. The complex peptide product will be commercialized by Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe and the UK. The agreement covers pan-European, UK, and India markets....
Back to Newsroom